Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Les Laboratoires Servier

http://www.servier.com/

Latest From Les Laboratoires Servier

InflaRx Undaunted By Dermatology Rivals

The group says INF904 can make billions in two highly competitive skin diseases, but this looks optimistic.

Clinical Trials Commercial

Agios Extends Cash Runway With $905m Royalty Pharma Deal

Deal Snapshot: Agios sold rights to a 15% royalty on US net sales of the IDH1/2 inhibitor vorasidenib, which it sold to Servier in 2020.

Deals Cancer

Verastem RAMPS Up In Rare Ovarian Cancer With Avutometinib/Defactinib Filing

The company announced topline data from the RAMP 201 trial in low-grade serous ovarian cancer, a rare disease with no FDA-approved treatments, and started a rolling FDA submission.

Clinical Trials Cancer

Glioblastoma Market Snapshot: Two Approvals In 2024 And A Rich Pipeline

Glioblastoma carries a grim prognosis. The biopharma industry is trying to improve patient outcomes, with 120 drugs in the pipeline and two anticipated approvals this year.

Market Intelligence Market Snapshot
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Biogaran SAS
    • Egis Pharmaceuticals plc
    • WeHealth
    • Servier BioInnovation
    • Symphogen A/S
    • Servier Pharmaceuticals, LLC.
UsernamePublicRestriction

Register